Artia Global Partners LP purchased a new stake in Travere Therapeutics, Inc. (NASDAQ: TVTX) in the s

Travere Therapeutics is rated Buy, with a DCF-based fair value of ~$81 per share, implying 27% upsid

HONG KONG, Aug 19, 2026 - (ACN Newswire) - Everest Medicines (01952.HK) announced its interim result

Travere Therapeutics NASDAQ: TVTX is pursuing growth through expanded use of FILSPARI in rare kidney

Bank of America Corp DE lessened its holdings in shares of Travere Therapeutics, Inc. (NASDAQ: TVTX)

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on August

Evercore ISI Group analyst Liisa Bayko maintains Travere Therapeutics (NASDAQ:TVTX) with a Outper

Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and

Wedbush analyst Laura Chico maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and ra

Travere Therapeutics is downgraded from Buy to Hold after a >130% rally, reflecting competitive risk

Empowered Funds LLC boosted its holdings in Travere Therapeutics, Inc. (NASDAQ: TVTX) by 2,719.8% in

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company m

TD Cowen analyst Tyler Van Buren maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and rais

Citigroup analyst Yigal Nochomovitz maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and r

Evercore ISI Group analyst Liisa Bayko maintains Travere Therapeutics (NASDAQ:TVTX) with a Outper

US stocks rise, Wynn Resorts beat earnings expectations, share price jumps 10.9%. Other companies re

Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises

Gainers Bluejay Diagnostics (NASDAQ:BJDX) shares moved upwards by 43.0% to $1.43 during Wednesday&#

Travere Therapeutics shares surged 13.44% after hours as strong revenue growth and FILSPARI sales ga

Travere Therapeutics NASDAQ: TVTX reported second-quarter results marked by record FILSPARI demand a

Travere Therapeutics, Inc. (TVTX) Q2 2026 Earnings Call Transcript

While the top- and bottom-line numbers for Travere (TVTX) give a sense of how the business performed

Travere Therapeutics (TVTX) came out with a quarterly loss of $0.37 per share versus the Zacks Conse

Gainers Bluejay Diagnostics (NASDAQ:BJDX) stock moved upwards by 42.0% to $1.42 during Tuesday'

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today reported its second quar

Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report

NEW YORK, July 27, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is inves

NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is i

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on July 1

HONG KONG, July 8, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK) announced the closing of

Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises

Wedbush analyst Laura Chico maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and ra

Evercore ISI Group analyst Liisa Bayko maintains Travere Therapeutics (NASDAQ:TVTX) with a Outper

Citigroup analyst Yigal Nochomovitz maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and r

Wells Fargo analyst Mohit Bansal maintains Travere Therapeutics (NASDAQ:TVTX) with a Overweight a

Patients in the study who initiated and remained on FILSPARI maintained durable and deepened protein

Citigroup analyst Yigal Nochomovitz maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and r

Wedbush analyst Laura Chico reiterates Travere Therapeutics (NASDAQ:TVTX) with a Outperform and m

HC Wainwright & Co. analyst Joseph Pantginis maintains Travere Therapeutics (NASDAQ:TVTX) wit

Civorebrutinib is an investigational oral, covalent reversible BTK inhibitor designed to provide dif

Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that the United States Patent and Trademark

Wells Fargo analyst Mohit Bansal maintains Travere Therapeutics (NASDAQ:TVTX) with a Overweight a

Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced its intention to offer, subject to market a

Travere Therapeutics (NASDAQ:TVTX) reported a profit in Q1, surpassing analyst estimates. Shares fel

TD Cowen analyst Tyler Van Buren maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and rais

Citigroup analyst Yigal Nochomovitz maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and r

Wedbush analyst Laura Chico maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and ra

HC Wainwright & Co. analyst Joseph Pantginis maintains Travere Therapeutics (NASDAQ:TVTX) wit

Travere Therapeutics (NASDAQ:TVTX) reported quarterly earnings of $0.05 per share which beat the ana